Johnson & Johnson (JNJ) closed the most recent trading day at $149.83, moving -0.52% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.57% for the day.

Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine after results failed to demonstrate sufficient efficacy.

In the latest market close, Johnson & Johnson (JNJ) reached $163.29, with a -0.21% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 1.77%.

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants. A number of companies have highlighted ...

In a world where business moguls and millionaires often take great pleasure in flaunting their wealth and power, George E. Johnson, early on, decided to assume the role of a compassionate coach.